|
|
Other links at Articles > Cardiology |
| 2. |
ARBs Unable to TRANSCEND Placebo in High-Risk Patients
|
|
|
The angiotensin-receptor blocker telmisartan has fared no better than placebo in TRANSCEND in patients at high-risk of cardiovascular disease unable to tolerate ACE inhibitors, seemingly providing more questions than answers. Heartwire
|
| 4. |
Improving Outcomes Through Early Intervention
|
|
|
Most of the pivotal PAH trials have focused on functional class III/IV patients. Recent studies have included class I/ II patients, suggesting that early treatment of these groups may be beneficial.
Medscape Pulmonary Medicine
|
|
|